New hope for Crohn's patients: study tests guselkumab after ustekinumab fails

NCT ID NCT07310095

Recruiting now Disease control Sponsor: Xian-Janssen Pharmaceutical Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether guselkumab can help people with Crohn's disease whose current treatment (ustekinumab) has stopped working. Crohn's disease causes severe gut inflammation. About 78 Chinese adults with active Crohn's will receive guselkumab and be followed for 48 weeks to see if their symptoms improve. The goal is to reduce inflammation and achieve remission without needing lifelong medication.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CROHN DISEASE

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Ruijin Hospital
RECRUITING

Shanghai, 200031, China
Sir Run Run Shaw Hospital Zhejiang University School of Medicine
RECRUITING

Hangzhou, 310018, China
The First Affiliated Hospital Sun Yat sen University
RECRUITING

Guangzhou, 510060, China
The First Affiliated Hospital of Anhui Medical University
RECRUITING

Hefei, 230022, China
The Sixth Affiliated Hospital Sun Yat sen University
RECRUITING

Guangzhou, 510655, China